IgG-Dependent Dismutation of Superoxide in Patients with Different Types of Multiple Sclerosis and Healthy Subjects

This work is the first to demonstrate that class G immunoglobulins (IgGs) in patients with multiple sclerosis and healthy individuals have the ability to catalyze the dismutation reaction of the superoxide anion radical. Thus, superoxide dismutase (SOD) activity is an intrinsic property of antibodies, which is confirmed by a number of stringent criteria. SOD activity of IgGs in patients with multiple sclerosis statistically significantly exceeds such activity in healthy individuals by 2-4 times. Moreover, the maximum activity has been registered in patients with relapsing remitting multiple sclerosis. The kinetic characteristics of the SOD reaction of IgGs are several orders of magnitude lower than those for the SOD enzyme but do not differ between patients with multiple sclerosis and healthy individuals. Consequently, abzymes with SOD activity have a lower catalysis rate than that of the enzymes and form a stronger complex with the substrates. Inhibitory analysis showed that this activity is inhibited by classical metal-dependent SOD inhibitors. The activity of IgGs was inhibited by classical metal-dependent inhibitors EDTA and TETA (triethylenetetramine). Also, high catalase activity of IgGs was detected in these patients. We suggest that these abzymes help protect the body from oxidative stress.

Download Full-text

Reduced ErbB4 Expression in Immune Cells of Patients with Relapsing Remitting Multiple Sclerosis

Multiple Sclerosis International ◽

10.1155/2011/561262 ◽

2011 ◽

Vol 2011 ◽

pp. 1-7 ◽

Cited By ~ 4

Author(s):

Evgenia Tynyakov-Samra ◽

Eitan Auriel ◽

Yifat Levy-Amir ◽

Arnon Karni

Keyword(s):

Multiple Sclerosis ◽

Flow Cytometry ◽

Monoclonal Antibodies ◽

Immune Cells ◽

Oligodendrocyte Progenitor Cells ◽

Healthy Controls ◽

Healthy Individuals ◽

Neuregulin 1 ◽

Relapsing Remitting ◽

Relapsing Remitting Multiple Sclerosis

Background.There is an insufficient remyelination in the lesions of multiple sclerosis (MS). One of the factor that was found to promote remyelination is neuregulin-1 which is the ligand of ErbB4. Immune cells have been implicated in neurogenesis and oligodendrogenesis.Aims.We studied the expression of ErbB4 in the immune cells of patients with relapsing remitting (RR) multiple sclerosis (MS) and healthy controls.Methods.ErB4 expression in immune cells was studied by flow cytometry without stimulation or with stimulation with anti-CD3 and anti-CD28 monoclonal antibodies or in the presence of interferon-g or TNF-αas well as by immunoprecipitation and Western blot, and its mRNA was studied by real-time PCR.Results.We found reduced levels of ErbB4 in the total PBMCs and in T cells, monocytes, and B cells of RR MS patients. Similarly, the ErbB4 RNA levels were reduced in the immune cells of patients with RR-MS. Stimulation via CD3 and CD28 significantly upregulated the expression of ErbB4 on immune cells healthy individuals. This effect was weaker in the patients group.Conclusion.ErbB4 may play a role in the proliferation of oligodendrocyte progenitor cells, differentiation of oligodendrocytes, and remyelination, and, therefore, the reduced ErbB4 expression in immune cells of patients with RR-MS may contribute to insufficient remyelination that occurs in the disease.

Download Full-text

Comparison of the Patients Suffering from Relapsing-Remitting Multiple Sclerosis with Healthy Individuals regarding Serum Selenium and Zinc Levels

Avicenna Journal of Clinical Medicine ◽

10.52547/ajcm.27.3.157 ◽

2020 ◽

Vol 27 (3) ◽

pp. 157-163

Author(s):

Ali Asghar Vahidinia ◽

Mehrdokht Mazdeh ◽

Salahadin Adman ◽

Zahra Cheraghi ◽

◽

...

Keyword(s):

Multiple Sclerosis ◽

Serum Selenium ◽

Healthy Individuals ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Zinc Levels ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Evaluation of mir-377-3p Expression in Patients with Multiple Sclerosis

SciMedicine Journal ◽

10.28991/scimedj-2019-0102-2 ◽

2019 ◽

Vol 1 (2) ◽

pp. 48-54 ◽

Cited By ~ 1

Author(s):

Majid Amini Khorasgani ◽

Parisa Mohammady Nejad ◽

Mohammad Mehdi Moghani Bashi ◽

Mohammad Hedayati

Keyword(s):

Multiple Sclerosis ◽

Superoxide Dismutase ◽

Healthy Subjects ◽

Chromosomal Region ◽

Area Under The Curve ◽

Diagnostic Value ◽

Healthy Individuals ◽

Relapsing Remitting ◽

History Of ◽

Relapsing Remitting Multiple Sclerosis

One of the most recent studies in the field of genetics is to investigate the role of microRNAs as biomarkers for the diagnosis of multiple sclerosis. It is an inflammatory and degenerative disease of the central nervous myelin, which is manifested in numerous small and large plaques in the white matter of the brain and spinal cord. Formerly called has-miR-377-3p, miR-377-3p is located within the chromosomal region 32q14, and is located in the SOD gene. SOD (Superoxide Dismutase) is a gene located on chromosomal region 22q21 and the protein encoded by this gene is the superoxide dismutase enzyme. The aim of this study was to evaluate the expression of miR-377 in people with RRMS (Relapsing-Remitting Multiple Sclerosis) and healthy individuals in the Isfahan population. The study included 49 patients with RRMS and 52 healthy individuals who had no history of autoimmune and inflammatory disease. Total RNA was extracted from the blood lymphocytes of the study subjects using Ficol and Trizol and then made using miRNA cDNA, cDNA specific kit, and expression was measured by real-time RT PCR in healthy subjects and patients. Was. According to the results, miR-377-3p expression was higher in patients than in healthy subjects (P = 0.036) and the sensitivity and diagnostic value of miRNA was AUC = 0.80 (Area under the Curve). ) is. The results were consistent with previous studies and miR-377-3p could be used as a biomarker for the diagnosis of Multiple Sclerosis.

Download Full-text

FEATURES OF CYTOKINE PROFILE IN PATIENTS WITH DIFFERENT TYPES OF MULTIPLE SCLEROSIS

Immunology and Allergy: Science and Practice ◽

10.37321/immunology.2020.01-02 ◽

2020 ◽

pp. 12-16

Author(s):

Nataliia Vdovichenko ◽

Oleh Koliada ◽

Oleksandr Tupotilov

Keyword(s):

Multiple Sclerosis ◽

Serum Levels ◽

Enzyme Linked Immunosorbent Assay ◽

Healthy Individuals ◽

Laboratory Markers ◽

Disability Status ◽

Relapsing Remitting ◽

Different Types ◽

Pathogenetic Therapy

Purpose of the study In order to determine the serum levels of cytokines of patients in Kharkov and Kharkov region with relapsing-remitting and progressive types of multiple sclerosis (MS) at different periods of disease activity, as well as to establish a relationship between the state of the regulatory immunity, progression of MS and the degree of EDSS (Expanded Disability Status Scale) of patients, 98 patients with MS, as well as 27 healthy individuals, were examined. Material and methods. To determine the content of serum cytokines we used the method of enzyme-linked immunosorbent assay. An elevated levels of IFN-g, IL-1b and IL-12 were revealed in groups with RRMS. At the same time, in the group of patients with RRMS at the stage of clinical and radiological remission, increased production of IL-1b and IL-12 was accompanied by a compensatory increasing of IL-10 level. The results. An imbalance of cytokines was observed in patients with progressive MS. Regardless of the stage of progression an increased levels of IL-1b, IL-12 and IFN-g were observed, more expressed in patients with progressive MS than in patients with relapsing-remitting MS. Аt the same time, the level of IL-10 was reduced. The presence of a correlation between the EDSS and the level of IL-1b (r = 0.349, p = 0.031) and a negative correlation between the rate of disability and the level of IL-10 (r = -0.4371, p = 0.0414) were detected in patients with progressive types of MS at the stage of steady progression. Conclusions. Therefore, the determination of clinical and laboratory markers of the MS activity is of great importance for predicting the activity of the disease, the alternative of further treatment tactics and monitoring the effectiveness of pathogenetic therapy.

Download Full-text